|
13 Sep 2025 |
Dr. Reddy's Labs
|
Consensus Share Price Target
|
1316.70 |
1287.37 |
- |
-2.23 |
hold
|
|
|
|
|
24 Aug 2023
|
Dr. Reddy's Labs
|
Geojit BNP Paribas
|
1316.70
|
6212.00
|
5907.15
(-77.71%)
|
Target met |
Hold
|
|
|
|
|
27 Jul 2023
|
Dr. Reddy's Labs
|
Motilal Oswal
|
1316.70
|
5240.00
|
5507.00
(-76.09%)
|
Target met |
Neutral
|
|
|
|
|
27 Jul 2023
|
Dr. Reddy's Labs
|
SMC online
|
1316.70
|
|
5507.00
(-76.09%)
|
Pre-Bonus/ Split |
Results Update
|
|
|
|
|
27 Jul 2023
|
Dr. Reddy's Labs
|
ICICI Securities Limited
|
1316.70
|
6000.00
|
5475.65
(-75.95%)
|
Target met |
Accumulate
|
|
|
Dr. Reddy’s (DRL) delivered a strong beat in EBITDA and profit, driven by incremental sales from its base product portfolio and gRevlimid in the US. gRevlimid continues to lift overall margins; however, additional sales from products that are in shortage in the US improved base business margins in Q1FY24.
|
|
27 Jul 2023
|
Dr. Reddy's Labs
|
Axis Direct
|
1316.70
|
6000.00
|
5507.00
(-76.09%)
|
Target met |
Hold
|
|
|
We have HOLD on the stock
|
|
27 Jul 2023
|
Dr. Reddy's Labs
|
Prabhudas Lilladhar
|
1316.70
|
5150.00
|
5507.00
(-76.09%)
|
Pre-Bonus/ Split |
Sell
|
|
|
|
|
04 Jul 2023
|
Dr. Reddy's Labs
|
Sharekhan
|
1316.70
|
5963.00
|
5178.35
(-74.57%)
|
Target met |
Buy
|
|
|
|
|
23 Jun 2023
|
Dr. Reddy's Labs
|
Motilal Oswal
|
1316.70
|
4680.00
|
4993.90
(-73.63%)
|
Pre-Bonus/ Split |
Neutral
|
|
|
|
|
11 May 2023
|
Dr. Reddy's Labs
|
Prabhudas Lilladhar
|
1316.70
|
4500.00
|
4532.00
(-70.95%)
|
Target met |
Sell
|
|
|
|
|
11 May 2023
|
Dr. Reddy's Labs
|
Motilal Oswal
|
1316.70
|
4500.00
|
4532.00
(-70.95%)
|
Target met |
Neutral
|
|
|
|